Regenerative medicine for osteonecrosis of the femoral head : present and future.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Targeting AHNAK ameliorates osteonecrosis of the femoral head and affects adipogenic pathways involving Smad/PPARγ.Bone & joint research · 2026
   Article
2. Cystic lesions in osteoarthritis and osteonecrosis of the femoral head : a comparative analysis of 3D distribution, microstructure, and histology.Bone & joint research · 2025
   Article
3. Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis.Scientific reports · 2025
   Article
4. Polydopamine grafting polyether ether ketone to stabilize growth factor for efficient osteonecrosis repair.Scientific reports · 2025
   Article
5. Treatment of osteonecrosis of the femoral head with multiple drilling and bone marrow mesenchymal stem cells expandedAmerican journal of stem cells · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as